Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis: A Quasi-experimental Case-series Study.

IF 5.1 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Journal of Clinical Endocrinology & Metabolism Pub Date : 2025-08-07 DOI:10.1210/clinem/dgaf077
Nektaria Papadopoulou-Marketou, Anna Papageorgiou, Nikolaos Marketos, Panagiotis Tsiamyrtzis, Georgios Vavetsis, George P Chrousos
{"title":"Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis: A Quasi-experimental Case-series Study.","authors":"Nektaria Papadopoulou-Marketou, Anna Papageorgiou, Nikolaos Marketos, Panagiotis Tsiamyrtzis, Georgios Vavetsis, George P Chrousos","doi":"10.1210/clinem/dgaf077","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Osteoporosis is characterized by reduced bone mineral density (BMD) and disrupted microarchitecture estimated by trabecular bone score (TBS). Osteostrong® is a bone-strengthening system implementing 4 devices and incorporating brief (10-minute), weekly, low-impact, high-intensity osteogenic loading exercises. The aim of this study was to assess changes in BMD and TBS in the lumbar spine and/or hip over 12 months in peri-/post menopausal women with Osteoporosis following Osteostrong® intervention and to compare these outcomes with women who did not receive such intervention.</p><p><strong>Methods and subjects: </strong>A quasi-experimental case-series study in which 147 participants were separated into 2 groups, following informed consent: 75 in group A receiving Osteostrong® (subgroup G1 without and G2 with antiresorptive medication); and 72 in group B without Osteostrong® (subgroup G3 without and G4 with antiresorptive medication). Changes in lumbar spine and hip BMD and/or TBS were assessed at inclusion and 12 months later. Bonferroni-adjusted non-parametric paired tests examined for significant paired mean differences within each subgroup.</p><p><strong>Results: </strong>After Bonferroni adjustment, significant increases were observed in lumbar spine BMD in G2 (mean paired change: 0.029 g/cm2; Bonferroni-adjusted p < 0.001), and G4 (mean paired change: 0.025 g/cm2; Bonferroni-adjusted p = 0.05) as well as BMD-total hip left in G2 (mean paired change: 0.028 g/cm2; Bonferroni-adjusted p = 0.05). Other within-group changes in femoral neck BMD, total hip BMD, and TBS did not retain significance following Bonferroni correction.</p><p><strong>Conclusion: </strong>The Osteostrong® intervention showed modest lumbar spine BMD improvements over 12 months; some subgroup effects were significant but not when Bonferroni-adjusted, warranting cautious interpretation and further randomized trials.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e2878-e2887"},"PeriodicalIF":5.1000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342362/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf077","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Osteoporosis is characterized by reduced bone mineral density (BMD) and disrupted microarchitecture estimated by trabecular bone score (TBS). Osteostrong® is a bone-strengthening system implementing 4 devices and incorporating brief (10-minute), weekly, low-impact, high-intensity osteogenic loading exercises. The aim of this study was to assess changes in BMD and TBS in the lumbar spine and/or hip over 12 months in peri-/post menopausal women with Osteoporosis following Osteostrong® intervention and to compare these outcomes with women who did not receive such intervention.

Methods and subjects: A quasi-experimental case-series study in which 147 participants were separated into 2 groups, following informed consent: 75 in group A receiving Osteostrong® (subgroup G1 without and G2 with antiresorptive medication); and 72 in group B without Osteostrong® (subgroup G3 without and G4 with antiresorptive medication). Changes in lumbar spine and hip BMD and/or TBS were assessed at inclusion and 12 months later. Bonferroni-adjusted non-parametric paired tests examined for significant paired mean differences within each subgroup.

Results: After Bonferroni adjustment, significant increases were observed in lumbar spine BMD in G2 (mean paired change: 0.029 g/cm2; Bonferroni-adjusted p < 0.001), and G4 (mean paired change: 0.025 g/cm2; Bonferroni-adjusted p = 0.05) as well as BMD-total hip left in G2 (mean paired change: 0.028 g/cm2; Bonferroni-adjusted p = 0.05). Other within-group changes in femoral neck BMD, total hip BMD, and TBS did not retain significance following Bonferroni correction.

Conclusion: The Osteostrong® intervention showed modest lumbar spine BMD improvements over 12 months; some subgroup effects were significant but not when Bonferroni-adjusted, warranting cautious interpretation and further randomized trials.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
绝经后骨质疏松症的有效、简短、低影响、高强度的成骨负荷。
背景:骨质疏松症的特征是骨密度(BMD)降低和微结构破坏,由骨小梁评分(TBS)评估,导致骨折风险增加。“Osteostrong®”是一种骨骼强化系统,采用4种设备,并结合简短(10分钟),每周,低冲击和高强度的成骨负荷练习。我们评估了Osteostrong®干预对绝经后骨质疏松症妇女的疗效。方法和对象:147名绝经后骨质疏松症妇女分为两组:A组74名接受Osteostrong®干预治疗的妇女(平均年龄58.8岁,56.6-61岁,95% CI),再分为不接受抗吸收药物治疗的G1组和接受抗吸收药物治疗的G2组。B组包括73名未接受Osteostrong®干预的妇女(平均年龄61.8岁,59.4-64.1 95% CI),再细分为未接受抗吸收治疗的G3组和接受抗吸收治疗的G4组。所有参与者都进行了身体检查,并对继发性骨质疏松症进行了评估。在试验纳入时和12个月后进行双能x射线吸收仪(DXA)检查(Horizon W [S/N 300472M])。结果:在以下参数中观察到有统计学意义的增加:i)腰椎骨密度(L1-L4)在G1期(p=0.0039), G2期(p=0.0039)。结论:骨强®改善了骨质疏松症妇女的腰椎骨密度,无论是在抗吸收治疗中还是在抗吸收治疗中。此外,Osteostrong®增强了抗吸收治疗对脊柱、髋关节和股骨颈的骨密度和TBS的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Clinical Endocrinology & Metabolism
Journal of Clinical Endocrinology & Metabolism 医学-内分泌学与代谢
CiteScore
11.40
自引率
5.20%
发文量
673
审稿时长
1 months
期刊介绍: The Journal of Clinical Endocrinology & Metabolism is the world"s leading peer-reviewed journal for endocrine clinical research and cutting edge clinical practice reviews. Each issue provides the latest in-depth coverage of new developments enhancing our understanding, diagnosis and treatment of endocrine and metabolic disorders. Regular features of special interest to endocrine consultants include clinical trials, clinical reviews, clinical practice guidelines, case seminars, and controversies in clinical endocrinology, as well as original reports of the most important advances in patient-oriented endocrine and metabolic research. According to the latest Thomson Reuters Journal Citation Report, JCE&M articles were cited 64,185 times in 2008.
期刊最新文献
Transforming Women's Health Research-The Time Is Now. Elucidating the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Intolerance in People With Cystic Fibrosis. Wake Up and Smell-the Cortisol? Diabetes Risk in Young Survivors of Childhood Cancer: A Need for Prevention and Survivor-specific Treatment Strategies. Unraveling the Complexity of Primary Ovarian Insufficiency Genetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1